There is continued controversy as to the sequential steps and mechanism(s) responsible for the in vivo acquisition of multiple mutations during neoplastic transformation. We investigated the in vivo clonality and mutational spectra of hypoxanthine-guanine phosphoribosyltransferase (HPRT) mutations in T cells from children with acute lymphocytic leukemia (ALL) to gain insight into the mutagenic mechanisms associated with leukemogenesis. We observed several instances of multiple, independent HPRT mutations accumulating in vivo in T cell receptor (TCR) gene defined clones that had undergone extensive pre-and/or post-thymic expansion following chemotherapy. In addition, we also detected the accumulation of multiple unique single mutations within distinct expanding postthymic T cell clones. This pattern of clonally restricted hypermutability is compatible with extensive cell proliferation and selection alone without postulating genomic instability. These observations provide a paradigm for a continuum of cellular events that eventually results in the clonal accumulation of mutations in selected populations of cells in vivo and may provide insight into the primary genetic events associated with leukemogenesis, as well as the development of second malignancies and drug resistance following chemotherapy. Leukemia (2001Leukemia ( ) 15, 1898Leukemia ( -1905 
Introduction
Malignant transformation involves the accumulation of somatic mutations that results in uncontrolled growth of specific clonal lineages. Despite enormous progress in understanding both the genetic alterations and cellular perturbations observed in neoplastic cells, how these events occur over a clinically relevant time period remains unclear. Recent studies have estimated that thousands of mutational events may be found in a malignant cell population, 1,2 especially of lymphoid origin. The most accepted mechanism is the early development of genomic instability resulting in an increase rate of mutations in clonal lineages. [3] [4] [5] [6] In fact, such sequential acquisitions in single genomes rather than in a population of neoplastic cells have rarely been demonstrated. Rather, the detection of microsatellite instabilities derived from mutations in DNA mismatch repair genes in a large population of neoplastic cells from a variety of tumors [7] [8] [9] [10] has provided support for genomic instability being an early event in producing the multiple genetic alterations associated with malignant transformation. Alternatively, it has been postulated that extensive in vivo cell proliferation coupled with selection for a mutant phenotype without loss of genomic stability can lead to the accumulation of the requisite number of somatic mutations for malignant transformation. [11] [12] [13] [14] In this scenario, the original stimulus to cell proliferation is the primary 'event' in produc- ing cancer. This stimulus may be external or arise de novo, following mutations that confer selective growth advantages.
The analysis of somatic mutational events in humans has been accomplished by a variety of methods. Mutations at the hypoxanthine guanine phosphoribosyltransferase (HPRT) gene in peripheral blood T cells are widely used reporters of in vivo mutations in humans. HPRT mutant frequencies (Mf) in nonmutagen-exposed individuals are age dependent, ranging from 0.5-4 × 10 −6 in children, and increase 2-5% per year after adolescence. [15] [16] [17] [18] [19] Elevations over these levels are observed following exposures to genotoxic agents. [20] [21] [22] Molecular analyses of HPRT mutations have revealed spectra that not only differ between children and adults but also show changes associated with exposures to specific mutagens. [23] [24] [25] [26] As a result, the analysis of HPRT T cell Mfs and mutational spectra have been well-established quantitative and qualitative measures, respectively, of in vivo spontaneous mutational events and genotoxicity in humans.
In addition, the analysis of HPRT mutations can reveal T cell kinetics, clonal proliferation, and mutagenic mechanisms when analyzed in the context of T cell receptor (TCR) gene rearrangements of the mutants. TCR gene rearrangements occur in individual T cells in vivo during their intra-thymic differentiation, establishing developmental reference points for other in vivo cellular events such as somatic mutations as well as an unambiguous molecular signature for identifying clonal lineages. Characterizing HPRT mutational changes relative to TCR gene rearrangements has revealed patterns indicating in vivo clonal amplifications of mutant cells in many individuals. 27 Such amplifications, coupled with the failure to find similar patterns among non-mutant/wild-type T cells, have implicated cell proliferation as mutagenic to T cells in vivo. This, coupled with the observation that HPRT Mfs are from three-to five-fold higher in CD45RO
+ memory cells than in CD45RA
+ naive cells from the same individual give strong support for the mutagenic role of cell proliferation in T cells. 28 We have previously utilized this approach to characterize the evolution of clonally restricted genomic instability in children treated for acute lymphocytic leukemia (ALL). 29 In these children, mutant isolates derived from TCR gene defined T cell clones demonstrated the progressive acquisition of multiple independent mutations in the same HPRT molecule. Independence of the events was demonstrated by their sequential rather than simultaneous occurrence.
We now describe the in vivo accumulation of multiple unique single HPRT mutations in non-malignant TCR gene defined T cell clones from children with ALL following treatment as a result of extensive pre-and/or post-thymic clonal proliferation ('proliferative' mutations). In some cases these proliferative mutations arose in the same treated ALL patients in whom clones with genomic instability were previously observed. 29 Therefore, although the mutational patterns described here can be explained by cell proliferation and selection alone, they may be part of the overall process that eventually leads to clonally restricted genomic instability. These studies demonstrate that cell proliferation, selection and somatic mutation are intimately related in these patients, suggesting a unifying hypothesis as to how the clonal accumulation of somatic mutations becomes manifest in vivo.
Patients and methods

Patients
Peripheral blood samples were obtained from subjects with ALL at the time of diagnosis, during treatment, and in remission at the Pediatric Oncology Clinic at the University of Vermont as previously described. 29 Subjects at the time of bone marrow relapse were also recruited from other Pediatric Oncology Group (POG) institutions prior to the start and during treatment. Informed consent was obtained following procedures approved by the Committee on Human Research at the University of Vermont and POG institutions. Although treatments differed, they were completed in approximately 2. years and included methotrexate, prednisone, as well as an alkylating agent such as cyclophosphamide and an anthracycline for some high-risk patients. All the therapies also included long-term treatment with purine analogues such as 6-thioguanine or 6-mercaptopurine which have been shown to positively select in vivo for cells deficient in HPRT activity, 30 the deficiency that characterizes the HPRT mutant T lymphocytes used as reporters of somatic mutation.
T cell HPRT mutant frequencies (Mfs) were previously determined using the HPRT cloning assay 31 for 19 subjects at the time of diagnosis, 32 subjects in remission and 58 subjects at the time of recurrence. 29 Many of these children have also been studied longitudinally during and following the completion of therapy as part of a large-scale genotoxic biomonitoring study investigating the short-and long-term genetic consequences of chemotherapeutic treatment on children. At initial diagnosis HPRT Mfs ranged from 0.2 to 3.4 × 10 −6 with a mean of 1.23 × 10 −6 , which are not statistically different from controls. 16, 29 Following chemotherapy, HPRT Mfs for patients in remission ranged from 3.3 to 4304 × 10 −6 with a mean of 331 × 10 −6 while those for patients at relapse ranged from 1 to 4941 × 10 −6 , with a mean of 303 × 10 −6 which is significantly increased (P Ͻ 0.001) compared to controls, and ALL patients before treatment. 29 Thirty-one percent of patients in remission, and 24% of subjects at relapse had Mfs Ͼ30-fold higher than age-matched controls following chemotherapy.
Molecular analysis of HPRT mutant isolates
Molecular analysis on 155 HPRT mutant isolates from 12 subjects with Mfs Ͼ30-fold above normal (Mf = 177-4304 × 10 −6 , Table 1 ) was performed to screen for multiple HPRT mutational events in proliferating T cell clones. Six subjects were in clinical remission following the completion of therapy while seven subjects were studied at the time of relapse either following the completion of therapy or while on the initial chemotherapy (CS100 B1), Table 1 .
HPRT mutant isolates were characterized at the genomic and/or cDNA level. The coding region for HPRT (located at Xq26) is 670 bp long; the gene is 43 kb in size. Welldeveloped molecular techniques are available for analyses of mutant cells. 24, 32, 33 Previously observed HPRT mutations Leukemia include base substitutions at more that 270 sites in all nine exons, small deletions and insertions, large structural alterations, splice site changes in introns and specialized genetic events such as V(D)J recombinase-mediated deletions. 23, 34 Since the HPRT gene is located on the X-chromosome, molecular analyses at the DNA/RNA level were performed in a different way for mutant isolates from males and females. 24 Mutant isolates from males were first analyzed by multiplex genomic HPRT PCR to determine the presence or absence of the nine HPRT exons. 33, 35 Mutant isolates from males showing no genomic alterations were characterized by reverse transcriptase (RT) PCR and DNA sequencing of cDNA amplified products. 24 The multiplex PCR primer pairs for exons 1-9, also permitted sequence analyses of both intron and exon segments involved in most splice-site mutations, reflected as exon exclusions or intron inclusions in cDNA. For mutant isolates from females, multiplex genomic PCR analysis was not performed because the inactive X-chromosome precludes deletion determination. Therefore, HPRT mutant isolates from females were first analyzed with specific primers to screen for V(D)J recombinase-mediated exon 2-3 deletion mutants. 23 Those mutant isolates that showed no V(D)J recombinase-mediated deletions were then analyzed by RT-PCR and subsequent DNA sequencing of cDNA amplified products. 24 
Determination of clonal lineages in T cell mutant isolates
Clonality determination of HPRT mutant T cells was defined by TCR␤ gene rearrangement patterns for all isolates recovered from each subject by performing a two-step PCR amplification and subsequent sequencing of the highly polymorphic CDR3/variable regions of TCR␤. 29 These rearrangements provide temporal reference points for other events that occur in undifferentiated (pre-thymic) or differentiated (post-thymic) T cells. Composite patterns of HPRT mutational changes and TCR gene CDR3 sequences for multiple mutant isolates obtained from an individual were interpreted, as outlined in Figure 1 . Two or more mutant isolates having the same HPRT mutation and TCR gene CDR3 sequences were defined as 'sibling' HPRT mutants derived from a single HPRT mutation arising in a post-thymic TCR gene defined T cell clone ( Figure 1 , pattern A). Two or more mutant isolates having different HPRT mutations but sharing the same CDR3 sequence were defined as independent HPRT mutational events occurring in the same in vivo post-thymic T cell clone (Figure 1, pattern B) . Two or more mutant isolates with different HPRT mutations and CDR3 sequences were defined as distinct HPRT mutations occurring in different post-thymic T cell clones (Figure 1 , pattern C). Finally, two or more mutant isolates having the same HPRT mutations but showing different CDR3 sequences were defined as a single HPRT mutational event in a pre-thymic T cell clone prior to TCR gene rearrangement ( Figure 1 , pattern E). An alternative interpretation for this last pattern could be independent HPRT mutations in a mutational 'hot spot' if the T cell mutants were recovered from different individuals (Figure 1, pattern D) .
Results
Somatic mutations in clonally restricted proliferating T cell lineages
Eight HPRT mutant isolates recovered from subject CS75 illustrate post-thymic T cell clonal proliferation in two different ); 6-11 years old (3.5 × 10 −6 ); and 12-16 years old (3.7 × 10 −6 ). b Each of these samples was obtained at the time of diagnosis with recurrent ALL prior to the start of relapse ALL therapy. c Sample CS143 B2 was obtained 4 weeks after the start of therapy for relapsed ALL, the end of the induction phase, 230 weeks following start of initial therapy. d Sample CS100 B1 was obtained at the time of ALL relapse, during week 69 of the initial maintenance therapy for ALL.
Figure 1
The association between HPRT mutations and TCR␤ CDR3 gene patterns in mutant isolates.
TCR gene defined clones (Tables 2 and 3) . A single complex HPRT mutation (deletion of bp 319-351, G 352 → T transversion and deletion of bp 363-384) was recovered in six independent isolates of the clone designated by its CDR3 amino acid sequence QDMPRAS. This mutation was considered to be a single complex event rather than a series of multiple events because there is no evidence among the several isolates of their sequential acquisition and the close proximity of the molecular changes within the HPRT allele. Another HPRT mutation, IVS5+ 1 G → T (a 67 bp exon 5 splice site insertion mutation), in clone GLAGF, was recovered in two mutant isolates from this patient. Post-thymic T cell proliferation was also seen in subject CS33 who completed treatment and in four patients who relapsed (CS143, CS183, CS142, and CS126) (Tables 2 and 3 , and Figure 2 ). Of note, the TCR gene defined clone TQTGST in patient CS142 shows a V(D)J recombinase-mediated HPRT deletion, confirming that these clinically important gene rearrangement mutations can be amplified in vivo. 23 Extensive in vivo pre-thymic proliferation of HPRT mutant clones was also observed. In subject CS233, four independent mutant isolates were recovered containing an HPRT base substitution mutation (G 580 → C) each with a unique TCR CDR3 gene region defined by amino acid sequences, QEDS, ERDKS, TRDTY and GLAGH (Tables 2 and 3 ). Four additional mutant isolates with apparently identical non-V(D)J recombinasemediated 2-3 deletions were also recovered from this subject with each expressing unique TCR gene sequences, FR, AGTK, LVDTGSG and one TCR clone without a CDR3 region. As with the G 580 → C mutation, this HPRT mutational event was amplified prior to acquisition of the TCR gene as shown by the progeny of post-thymic clones. Pre-thymic clonal prolifer- *Analysis of genomic DNA from these mutant isolates revealed no splice-site or exon mutations and as a result are designated as presumed deletions since they are from female subjects.
ation of HPRT mutant isolates was also observed in subjects CS98 and CS126 (Tables 2 and 3 , and Figure 2 ). In subject CS 126, one of its progeny sub-clones, LEQR, also exhibited postthymic proliferation.
Accumulation of HPRT mutations as a consequence of clonal proliferation
The above examples represent in vivo pre-and post-thymic proliferation of a TCR gene defined HPRT mutant clone characterized by a single mutation presenting in two or more isolates. Molecular analysis also revealed the in vivo accumulation of multiple distinct single HPRT mutations within mutant isolates of single TCR gene defined clones as a result of cellular proliferation, ie 'proliferative' mutations. The most striking example of proliferative mutations is illustrated by relapse patient CS58, in whom 10 different HPRT mutational events arose in mutant isolates from a single post-thymic T cell clone, SLAG (Tables 2 and 3 , and Figure 2) . Three of the post-thymic sub-clones (sub-clones defined now by their HPRT mutation) themselves show evidence of in vivo prolifer- ation. Altogether, 13/17 HPRT mutant isolates (76%) analyzed from patient CS58 arose in vivo in a single TCR gene defined post-thymic clone. We also observed in vivo clones manifesting proliferative mutations in subjects CS51 (clones G and DRVIA); CS142 (clone LAEG); CS126 (clone DLA) and CS100 (clone DFGGKG) (Tables 2 and 3 , and Figure 2 ).
Discussion
We report several examples where multiple isolates of the same TCR gene defined in vivo T cell clone harboring single identical HPRT mutations were recovered from individual subjects following treatments for ALL. By relating the HPRT mutational changes to the TCR gene rearrangement sequences for each mutant we were able to determine that some of the HPRT mutations arose in pre-thymic as well as in post-thymic proliferating clones. It is important to note that such examples of clonal proliferation are rarely observed for nonmutant/wild-type T cell isolates from humans. 36, 37 We also Leukemia described instances where mutant isolates of the same TCR gene defined clone harboring multiple but different T cell HPRT mutations were recovered from individual patients treated for ALL. In the extreme (subject CS58), 10 independent HPRT mutations arising in the TCR gene SLAG clone were recovered in a collection of 13 mutant isolates (Figure 2 ). Multiple mutations in single TCR gene defined clones arising in this way need not per se indicate genomic instability. Since the spontaneous mutation rate for HPRT is ෂ1 × 10 −6 per cell generation, this extreme observation could have occurred after 13 × 10 6 cell generations, and thus represent extensive clonal proliferation. In this context, restorative proliferation associated with our observations is not dependent on a mutational event. This is in contrast to true genetic instability, which requires a prior genetic or stable epigenetic change. The mutagenicity of the ALL treatments could also have been a factor in the mutational patterns described here, although it is not clear why randomly induced mutations should cluster in TCR gene defined clones.
We previously reported several examples in these same ALL-treated patients of TCR gene defined in vivo clones in which mutant isolates had multiple HPRT changes in the same allele/molecule as a result of genomic instability. 29 In this report we make a distinction between the pattern indicating genomic instability, ie the sequential accumulation of distinct mutations in the same allele and that associated with the accumulation of single multiple mutations in sibling isolates within specific proliferating T cell clones. In each case, observations were made in ALL patients who were receiving or who had received cytotoxic chemotherapy. Presumably all of the T cell clones in these patients that survived chemotherapy underwent cycles of extensive proliferation to restore cell numbers. Somatic mutations arose in these clones, probably in increased numbers (but not at increased rates), as a result of proliferation. Although the mutational process is not specific, we propose that in these subjects, mutations arising in vivo in HPRT are selected because of the long-term exposure to purine analogues during treatment. The HPRT mutants therefore are able to continue to proliferate, presumably overgrowing the non-mutant T cells that amplify more slowly. These factors alone can account for the elevation of HPRT Mfs in these patients and the composite HPRT-TCR gene patterns observed.
Selecting for any somatic mutation (eg HPRT) in a heterogeneous population of cells (eg T cells) also selects for those rare cells most likely to mutate as a result of true genomic instability. We have previously presented reasons why rare genetically unstable cells may be present in normal individuals. 38 The process then becomes progressive, resulting in non-selected mutations (eg the secondary and tertiary HPRT mutations in single alleles that already contain a primary selectable mutation) leading to the selection of clones with mutational patterns indicative of true genomic instability, as previously demonstrated in some of these ALL patients. 29 We hypothesize that our findings illustrate that chemotherapy resulting in apoptosis and restorative clonal expansion also results in a progressive sequence of cell proliferation, selection and the clonal accumulation of mutations in apparently normal T cells demonstrating an important inherent biologic potential in all cells.
Our observations in T cells in vivo also have their in vitro counterparts in both prokaryotic 39, 40 and eukaryotic cells. 41 In these cases, progressive rounds of mutation and selection for mutant phenotypes in heterogeneous populations of proliferating, wild-type cells eventually result in populations that are greatly enriched for proliferating cells that have genomic instability. Again, selecting for mutant cells in heterogeneous populations also selects for those cells most likely to mutate, with the power of the process presumably related to the degree of selection, proliferation, and the time involved.
We were able to recognize a process that eventually leads to clonally restricted proliferation of mutations with and without genomic instabilities in children treated for ALL because we studied a mutational event that produced an in vivo selective growth advantage. Even though the HPRT gene usually serves as a simple reporter biomarker in population studies, mutations at this locus may provide a growth advantage in the context of purine analogue chemotherapy. Therefore, under the selective stimulus of restorative proliferation following chemotherapy, mutant T cells have an in vivo growth advantage similar to what might transpire in early pre-malignant cells. Further studies with this approach should be useful in understanding the progression between early mutations, selection, and the multiple genetic and cellular changes observed during malignant transformation, second malignancies and/or the development of drug resistance.
